Analysts’ Recommendations for Merck in November 2017
In November 2017, the FDA approved Merck’s (MRK) Prevymis (letermovir) for the prevention of CMV (cytomegalovirus) infection and disease in adult CMV-seropositive recipients of allogeneic hematopoietic ...